TP53 and neoplasm: Our earlier results show that treatment with Minnelide is able to significantly reduce the CD133+ population in the spontaneous KPC (KrasG12D,Trp53 R172H,Pdx-1-Cre) murine model tumors and in human patient tumor derived xenografts [33].